XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income (loss) $ (15,434) $ 17,247
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 6,424 6,050
Amortization of marketable securities premium 18 50
Stock-based compensation 2,718 3,261
(Gain) Loss on disposal of equipment 18 (136)
Return of equity method investments as dividends 3,666 1,608
Equity in income of unconsolidated joint ventures (2,344) (5,308)
Deferred tax assets 122 165
Changes in operating assets and liabilities:    
Accounts receivable 9,594 (5,406)
Inventories (1,013) (32,659)
Prepaid expenses and other current assets 1,909 6,445
Other assets 219 (1,461)
Accounts payable (3,375) (1,635)
Accrued liabilities (1,742) (2,927)
Other long-term liabilities 1,194 5,405
Net cash provided by (used in) operating activities 1,974 (9,301)
Cash flows from investing activities:    
Purchases of property, plant and equipment (11,178) (28,765)
Purchases of available-for-sale debt securities   (2,160)
Proceeds from sales and maturities of available-for-sale debt securities 7,423 5,400
Proceeds from sales of equity securities - 15% of Jia Mei 827  
Investments in non-marketable equity investments (1,918)  
Net cash used in investing activities (4,846) (25,525)
Cash flows from financing activities:    
Proceeds from common stock options exercised 10 517
Proceeds from bank loans 42,197 42,352
Payments on bank loans (40,673) (9,826)
Proceeds from capital increase in subsidiary shares from noncontrolling interests 708 2,232
Net cash provided by financing activities 2,242 35,275
Effect of exchange rate changes on cash and cash equivalents, and restricted cash (1,418) (394)
Net increase (decrease) in cash and cash equivalents, and restricted cash (2,048) 55
Cash and cash equivalents, and restricted cash at the beginning of the year 41,348 36,763
Cash and cash equivalents, and restricted cash at the end of the period 39,300 36,818
Supplemental disclosure of non-cash flow information:    
Conversion of related party borrowings to Additional Paid-in Capital   1,887
Investment in subsidiary shares from noncontrolling interest 308 937
Bank loan proceeds paid directly to a third-party vendor, included in accounts payable   474
Sales of land and building to unconsolidated joint venture   976
Consideration payable in connection with construction in progress, included in accrued liabilities $ 3,315 $ 3,378